GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT03615066
- Locations
- 🇨🇦
University Health Network, Toronto General Hospital, Toronto Centre for Liver Disease, Toronto, Ontario, Canada
🇨🇦Toronto Liver Centre, Toronto, Ontario, Canada
🇰🇷Chung-Ang University Hospital, Seoul, Korea, Republic of
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT03582098
- Locations
- 🇬🇧
NHS Grampian, Aberdeen, United Kingdom
🇬🇧London Northwest University NHS Trust, Eastcote, United Kingdom
🇬🇧Cheltenham General Hospital, Cheltenham, United Kingdom
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAF
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 201
- Registration Number
- NCT03580668
- Locations
- 🇨🇦
Spectrum Health, Vancouver, Canada
🇨🇦Regina General Hospital, Regina, Canada
🇨🇦Clinique Medicale du Quartier Latin, Montréal, Canada
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 257
- Registration Number
- NCT03568929
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷University General Hospital of Patras, Patra, Greece
🇧🇪Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital, Antwerpen, Belgium
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 34
- Registration Number
- NCT03558139
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- 🇪🇸
Hospital Universitario Puera de Hierro Majadahonda, Majadahonda, Spain
🇪🇸CEIC Hospital Vall d'Hebron, Barcelona, Spain
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
- Conditions
- HIV-1/HBV Co-Infection
- Interventions
- Drug: B/F/TAFDrug: Placebo to match DTGDrug: Placebo to match F/TDFDrug: Placebo to match B/F/TAF
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 244
- Registration Number
- NCT03547908
- Locations
- 🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
🇨🇳Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸CHUVI - Hospital Universitario Alvaro Cunqueiro, Vigo, Spain
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT03491553
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Auckland, New Zealand
🇺🇸University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT03472326
- Locations
- 🇿🇼
Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals, Harare, Zimbabwe
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Drug: SELDrug: FIRDrug: CILODrug: Placebo to match FIRDrug: Placebo to match CILODrug: Placebo to match SEL
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 395
- Registration Number
- NCT03449446
- Locations
- 🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States